COMPARISON OF US, CT, MRI IN DETECTION AND STAGING OF OV

US、CT、MRI 在 OV 检测和分期方面的比较

• 批准号: 3550032
• 负责人: ULRIKE M HAMPER
• 金额: $ 16.45万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-09-30 至 1995-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3550032
• 关键词: clinical trials; computed axial tomography; diagnosis design /evaluation; diagnosis quality /standard; female; human subject; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; neoplasm /cancer relapse /recurrence; nuclear magnetic resonance spectroscopy; ovary neoplasms; ultrasound

This application is in response to RFA:CA-92-02 of the Radiologic Diagnostic Oncology Group IV entitled Ovarian Cancer and Pediatric Solid Tumors. It is responsive to ovarian cancer only. Our long term objective is to evaluate the relative roles of current and emerging imaging modalities in the diagnosis, staging and serial monitoring of ovarian cancer. Currently neither ultrasonography (US), computed tomography (CT) or magnetic resonance imaging (MRI) are widely used as screening methods for ovarian cancer. CT has been shown to carry a relatively high false negative rate for residual or recurrent disease. Magnetic resonance imaging has not been routinely used to stage ovarian cancer. The potential roles of ultrasonography, computed tomography, and magnetic resonance imaging will be determined in terms of their ability to detect and differentiate benign from malignant ovarian masses as well as their ability to stage extent of tumor by prospective trials. Using receiver operator characteristic (ROC) curves, we will compare the performance of each modality separately and then jointly. Appropriate diagnostic criteria for detection and staging of ovarian cancer will be determined as well as the optimal role of each imaging modality. We will test the hypothesis that CA-125 in combination with Color Flow Doppler US, CT or MRI can differentiate benign from malignant ovarian masses. In addition we will assess whether or not more effective cytoreductive surgery can be achieved by more accurate pre-operative staging using either optimized CT or optimized MRI imaging. The role of CT and MRI in monitoring patients with ovarian cancer after primary surgery will also be tested through sequential examinations and correlation with serial CA-125 tumor antigen and second look operations. We hypothesize that CA-125 in combination with CT and MRI may detect residual disease and thus avoid the need for a second-look surgery in most patients. Detailed surgical and pathologic correlations are proposed as measures of truth for both loco-regional extent and distant peritoneal spread of tumor. The data acquired through this prospective study will form the basis for developing a decision tree analysis for optimal imaging evaluation of ovarian cancer.

本申请是对《放射学》的RFA：CA-92-02的响应 诊断肿瘤学第四组：卵巢癌和儿科固体 肿瘤。它只对卵巢癌有反应。 我们的长期目标是评估当前和 新出现的影像方法在诊断、分期和系列化中的应用 卵巢癌的监测。目前，无论是超声检查(美国)， 计算机断层扫描(CT)或磁共振成像(MRI)被广泛应用 用作卵巢癌的筛查方法。CT已被证明具有 残留或复发疾病的假阴性率相对较高。 磁共振成像还没有被常规用于卵巢分期 癌症。超声检查、计算机体层摄影术和 磁共振成像将根据他们的能力来确定 同时检测和鉴别卵巢良恶性肿块 因为他们有能力通过前瞻性试验来判断肿瘤的程度。vbl.使用 接收操作员特性(ROC)曲线，我们将比较 分别表演每一种情态，然后联合表演。恰如其分 卵巢癌的诊断标准和分期将是 以及每种成像模式的最佳作用。我们会 CA-125与彩色血流多普勒联用的假说检验 超声、CT或MRI可鉴别卵巢良恶性肿块。在……里面 此外，我们将评估是否有更有效的细胞还原 手术可以通过更准确的术前分期来实现 优化的CT或优化的MRI成像。CT和MRI在脑血管疾病中的作用 对初次手术后卵巢癌患者的监测也将 通过顺序检查和与序列的关联进行测试 CA-125肿瘤抗原和二次手术。我们假设 CA-125联合CT、MRI可检出残留病变 从而在大多数患者中避免了二次手术的需要。详细 手术和病理的相关性被认为是真理的衡量标准。 对于肿瘤的局部区域范围和远处腹膜扩散。 通过这项前瞻性研究获得的数据将构成 开发用于最佳成像评估的决策树分析 卵巢癌。